Welcome to our dedicated page for Innovage Holding SEC filings (Ticker: INNV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InnovAge Holding Corp. filings document the reporting framework for a Nasdaq-listed healthcare services company built around the Program of All-inclusive Care for the Elderly (PACE). Form 8-K reports furnish quarterly operating results, financial-condition updates, Regulation FD investor presentations, guidance-related materials, and governance events such as director appointments and executive transitions.
Proxy materials describe annual meeting matters, classified-board elections, committee governance, executive and director compensation, stockholder voting procedures, and auditor ratification. The filings also identify InnovAge common stock on the Nasdaq Global Select Market and include emerging-growth-company status, common-stock registration details, capital-structure information, and public-company reporting obligations tied to its PACE care model.
InnovAge Holding Corp. filed a current report stating that it has posted a new investor presentation on its website. The company plans to use this presentation in meetings with investors, analysts and others, where it expects to reaffirm its full year fiscal 2026 guidance previously provided on May 5, 2026.
The disclosure is furnished under Regulation FD, meaning it is intended to share information broadly and is not treated as filed for liability purposes or automatically incorporated into other securities law filings.
InnovAge Holding Corp. appointed Jennifer Browne as President and Chief Operating Officer, effective June 8, 2026. She joins from Strive Health and previously held senior roles at Optum and DaVita in value-based care and population health.
Under her employment agreement, Browne will receive a $500,000 annual base salary, a one-time $200,000 sign-on bonus, and eligibility for an annual cash bonus targeted at 75% of base pay. She will receive an initial restricted stock unit grant valued at $500,000 plus ongoing annual RSU awards of similar value starting with fiscal 2027, each vesting over three years.
She is also being granted 1,260,000 Class B Units in TCO Group Holdings, L.P., with one-third vesting over three years based on time and two-thirds tied to performance hurdles measured by the Apax investor’s multiple on invested capital. As of March 31, 2026, InnovAge served about 8,050 participants across 20 centers in six states.
InnovAge Holding Corp. reported higher revenue but a larger quarterly loss for the period ended March 31, 2026. Total revenue rose to $251.9 million from $218.1 million a year earlier, driven by capitation payments. Net loss attributable to InnovAge widened to $29.5 million, or $0.22 per share, compared with a $11.4 million loss, largely reflecting higher corporate, general and administrative expenses.
For the first nine months of fiscal 2026, revenue increased to $727.8 million from $632.3 million, while net loss attributable to InnovAge narrowed to $10.8 million from $29.5 million. Operating cash flow improved to $43.4 million, and cash, cash equivalents and restricted cash reached $95.5 million. The company ended the quarter with $58.8 million of total debt and remained in compliance with its credit agreement covenants, while also recording substantial litigation-related accruals.
InnovAge Holding Corp. reported fiscal third-quarter 2026 results showing strong revenue growth but a larger net loss. Total revenues rose to $251.9 million, up about 15.5% from $218.1 million a year earlier, driven by higher PACE program volume.
Despite this growth, the company reported a net loss of $29.9 million versus a net loss of $11.1 million in the prior-year quarter, and its net loss margin widened to 11.9%. Results included substantial litigation costs and settlement charges of $51.9 million, which heavily affected GAAP profitability.
Operationally, Center-level Contribution Margin improved to $61.0 million, up nearly 50%, and Adjusted EBITDA increased to $30.5 million with a 12.1% margin, up from 4.9%. InnovAge ended the quarter serving about 8,050 participants and raised full-year 2026 guidance to total revenues of $950–$975 million and Adjusted EBITDA of $85–$90 million.
InnovAge Holding Corp. is meeting with investors and analysts at the KeyBank Capital Markets Healthcare Forum. During these meetings, the company expects to reaffirm its full year fiscal 2026 guidance that was previously provided in a February 3, 2026 press release about second fiscal quarter results ended December 31, 2026.
InnovAge has also posted the investor presentation used for these meetings on its Investor Relations website, making it publicly accessible. The information is being furnished under Regulation FD and is not deemed filed or incorporated by reference into other securities law filings unless specifically stated.
InnovAge Holding Corp. returned to profitability while growing revenue. For the quarter ended December 31, 2025, revenue rose to $239.7 million from $209.0 million, driven mainly by higher capitation revenue. Net income attributable to InnovAge was $10.6 million, versus a $13.2 million loss a year earlier, with diluted EPS improving to $0.08 from a loss of $0.10.
For the first half of fiscal 2026, revenue reached $475.8 million, up from $414.1 million, and net income attributable to InnovAge was $18.6 million compared with a $18.2 million loss. Operating cash flow improved to $25.3 million. The company ended the period with $83.2 million in cash and cash equivalents and $59.4 million of total debt, after refinancing its term loan and extending the maturity of its credit facilities.
InnovAge served about 8,010 PACE participants across 20 centers and continues to focus on managing external provider and care costs, which represented roughly 78% of revenue for the six-month period. Management highlights ongoing labor cost pressures, potential Medicaid changes under the One Big Beautiful Bill Act, and a California moratorium on most new PACE applications. The company is also responding to multiple civil investigative demands from federal and state agencies and is involved in several legal matters, including a securities class action settlement approved by the court and an arbitration and court case with a former pharmacy vendor.
InnovAge Holding Corp. filed a Form 8-K to furnish a press release announcing its financial results for the second fiscal quarter ended December 31, 2025. The press release is attached as Exhibit 99.1. The company clarifies this information is furnished, not filed, and is only incorporated into other filings if specifically referenced.
InnovAge Holding Corp. director reports no holdings in Form 3 filing. Sean Traynor, a director of InnovAge Holding Corp. (INNV), filed an initial beneficial ownership statement indicating that no non-derivative or derivative securities of the company are beneficially owned.
InnovAge Holding Corp. director files initial ownership report showing no holdings. Pavithra Mahesh, a director of InnovAge Holding Corp. (INNV), filed a Form 3 reporting that no non-derivative or derivative securities of the company are beneficially owned. The filing includes a power of attorney authorizing the signatory.
InnovAge Holding Corp. appointed Pavithra Mahesh and Sean Traynor to its Board of Directors, effective January 28, 2026. Mahesh will serve as a Class III director until the 2026 annual meeting, and Traynor as a Class I director until the 2027 annual meeting.
The Board increased in size to eleven directors with these appointments. Mahesh joined the Quality and Compliance Committee, while Traynor joined the Compensation, Nominating and Governance Committee. Both were designated under a director nomination agreement with the company’s principal shareholders and will not receive compensation for their Board service.